Related Experiment Video

Updated: May 10, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Targeted treatments for metastatic esophageal squamous cell cancer

Antonia Digklia1, Ioannis A Voutsadakis

  • 1Antonia Digklia, Ioannis A Voutsadakis, Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.

World Journal of Gastrointestinal Oncology
|June 27, 2013
PubMed

Insights

Targeted therapies show promise for esophageal squamous cell carcinoma (ESCC), a significant cancer in East Asia. While no targeted agents are approved, many are in clinical trials or show preclinical activity for metastatic ESCC.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Esophageal squamous cell carcinoma (ESCC) is a major subtype of esophageal cancer, prevalent in the upper and middle esophagus.
  • While incidence is declining in Western countries, ESCC remains a significant health concern, particularly in East Asia.

Purpose of the Study:

  • To review targeted treatment agents for esophageal squamous cell carcinoma (ESCC).
  • To discuss agents in advanced development for metastatic ESCC and promising drugs with preclinical or early clinical data.

Main Methods:

  • Literature review of targeted therapies for ESCC.
  • Analysis of clinical trial data and preclinical studies for novel agents.

Main Results:

  • No targeted therapy is currently FDA-approved for ESCC.
  • Several targeted agents are in clinical trials for metastatic ESCC.
  • Numerous agents demonstrate preclinical activity, warranting further clinical investigation.

Conclusions:

  • Targeted therapies represent a rational approach to ESCC treatment based on molecular alterations.
  • Ongoing research and clinical trials are crucial for developing effective targeted treatments for ESCC.
Keywords:
Clinical trialsEpidermal growth factor receptorEsophageal carcinomaMammalian target of rapamycinSquamousTargeted therapiesVascular endothelial growth factor receptor

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...